VIRTUS, a prospective, multicenter trial, demonstrates a twelve-month safety and effectiveness using a dedicated venous stent for ICVO demonstrate improvements in clinical symptoms and quality of life using the Venous Clinical Severity Score (VCSS) through 1-year follow-up.

Despite successful endovenous thermal ablation vein closure, a 5-year symptom recurrence rate of 20.9% after endovenous thermal ablation (EVTA) could be due to the presence of underlying ICVO.